Please upgrade your browser.
Renal function following partial nephrectomy is determined by the volume of renal tissue excised, the tumor location and patient age.
This Phase 2 trial of AV-951 for the treatment of patients with metastatic renal cell carcinoma (mRCC) exceeded enrollment goals with more than 270 patients participating..."
Atlanta can say hello with the rest of the nation to the new federal substitute for the advice of your doctor and your own best judgment: the Federal Coordinating Council for Comparative Effectiveness Research (CER).
"If Obama comes along and says everybody is going to have insurance the question will be how can we fund that."
Kidney cancer is an often fatal disease that has touched my family. Please do not support any so-called Comparative Effectiveness scheme that could ultimately result in my loved one not receiving the therapy preferred by the patient and doctor for the treatment of cancer.
Let's hope those over 70 years of age who voted for it don't find themselves in need of an operation the government thinks is just too expensive.
It is not the responsibility of our government to determine which drugs I should be able to receive for the treatment of my kidney cancer.
Kidney Cancer Association joins the ranks of those opposed to government-run comparative effectiveness schemes that could be used to deny patients expensive medications.
The authors present the first case report of complete histologic remission after neoadjuvant sunitinib treatment on primary renal tumour and vena cava thrombus.
Autoimmune phenomena during immunotherapy are associated with favorable outcomes in patients with metastatic renal cell carcinoma.
|Powered by NeonCRM|